Greenwich LifeSciences Azioni (NASDAQ: GLSI)

Ultime notizie per Greenwich LifeSciences (NASDAQ:GLSI) Azioni

Greenwich LifeSciences

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences Inc

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

LIPO

In the wake of Donald Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 presidential win</a>, Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has jumped 10% since Wednesday to reach $0.00001944.
Trump's victory, combined with the Republican Party's return to a Senate majority, signals a potential shift in U.S. economic policy that includes corporate tax cuts, high tariffs and an aggressive stance on inflation—factors that could reshape traditional and digital asset markets alike.
What To Know: A key driver of SHIB&#8217;s surge is Trump's pro-crypto stance, marked by his vision of the U.S. as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40671868/trumps-bitcoin-strategic-reserve-proposal-will-chip-away-dollars-status-warns-expert-money">"Bitcoin superpower."</a> Trump's proposal to incorporate Bitcoin into a national reserve has sent ripples through the crypto space, igniting excitement among investors who see digital assets as hedges against economic uncertainty. 
Trump's anticipated policies could stoke inflationary pressures, with JPMorgan analysts projecting up to a <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2.4% rise in inflation</a> if trade tariffs are fully enacted. In such an environment, investors often look to alternative assets like cryptocurrencies as protection against the dollar's decline. 
Shiba Inu, with its low entry price and high volatility, is a popular speculative asset among retail investors seeking both growth potential and a potential hedge against macroeconomic risks.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41825733/could-micas-passport-system-open-doors-across-europe-for-crypto-exchanges">Could MiCA&#8217;s Passport System Open Doors Across Europe For Crypto Exchanges?</a>
Shiba Inu was created as an Ethereum-based alternative to Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), branding itself as the "Dogecoin killer." Both coins share a meme-inspired appeal, drawing in retail investors with their playful branding and community-driven support.
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. <a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a> event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.

News

$DOGE

$SHIB

What's Going On With Shiba Inu (SHIB)?

Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.10 by 120 percent. The company reported quarterly sales of $64.877 million which beat the analyst consensus estimate of $57.180 million by 13.46 percent. This is a 19.46 percent decrease over sales of $80.553 million the same period last year.

Earnings

Earnings Beats

CMTG

Claros Mortgage Trust Q3 2024 Adj. EPS $0.22 Beats $0.10 Estimate, Sales $64.877M Beat $57.180M Estimate

Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.90) by 106.67 percent. The company reported quarterly sales of $1.667 million which beat the analyst consensus estimate of $611.000 thousand by 172.83 percent. This is a 250.95 percent increase over sales of $475.000 thousand the same period last year.

CBUS

Cibus Q3 2024 Adj. EPS $0.06 , Sales $1.667M Beat $611.000K Estimate

President-elect Donald Trump has appointed his campaign leader, Susie Wiles, as his chief of staff. This marks the first time in US history that a woman has been appointed to this influential position.
What Happened: Wiles, a seasoned GOP operative from Florida, will assume her new role when Trump takes office in January. Trump lauded Wiles for her pivotal role in his successful 2016 and 2020 campaigns, <a href="https://thehill.com/homenews/4979786-susie-wiles-chief-of-staff/">reported</a> The Hill.
&#8220;Susie is tough, smart, innovative, and is universally admired and respected. Susie will continue to work tirelessly to Make America Great Again,&#8221; said Trump, reported The Hill.
He said, &#8220;It is a well deserved honor to have Susie as the first-ever female Chief of Staff in United States history. I have no doubt that she will make our country proud.&#8221;
Wiles, known for her low-profile approach, spearheaded Trump&#8217;s Florida operations during the 2016 campaign and later collaborated with Ron DeSantis (R) on his gubernatorial campaign. However, she left DeSantis&#8217;s team due to escalating tensions.
The chief of staff role, second only to the president in terms of influence, will see Wiles managing Trump and his team, a task that proved challenging during his first term. Trump&#8217;s initial choice for the role, Reince Priebus, was replaced after six months by John Kelly, who later became a vocal critic of Trump.
See Also: <a href="https://www.benzinga.com/news/24/11/41710411/market-analyst-who-predicted-trumps-2016-win-and-bidens-2020-victory-now-sees-former-president-retak?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Market Analyst Who Predicted Trump&#8217;s 2016 Win And Biden&#8217;s 2020 Victory, Now Sees Former President Retaking The White House With &#8216;Large Majority Of Swing States&#8217;</a>
Why It Matters: Wiles&#8217; appointment comes on the <a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f">heels of Trump&#8217;s victory</a> in the 2024 presidential election. Trump&#8217;s win, which he described as &#8220;the greatest political movement of all time,&#8221; was followed by a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41807254/trump-election-raises-odds-of-roaring-2020s-scenario-veteran-wall-street-investor-s">surge in the U.S. stock market</a>, with analysts predicting a new &#8220;Roaring 2020s&#8221; scenario.
On Wednesday, after Trump won the election, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) shot up 2.5% to establish new record highs. The small-caps fund iShares Russell 2000 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) spiked 5.8%.
However, Trump also hinted at a <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">potential senior role</a> for Robert Kennedy Jr. to advance his &#8220;Make America Healthy Again&#8221; agenda, causing uncertainty in pharmaceutical stocks.
With Wiles at the helm as chief of staff, it remains to be seen how these developments will unfold and shape the course of Trump&#8217;s second term in office.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Trump Appoints Susie Wiles As First Woman Chief Of Staff In US History, Calls Her Tough, Smart And Innovative

Galiano Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#AMEX">GAU</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 40 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $71.130 million which missed the analyst consensus estimate of $78.000 million by 8.81 percent. This is a 5.22 percent increase over sales of $67.600 million the same period last year.

Earnings Misses

Galiano Gold Q3 2024 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $71.130M Miss $78.000M Estimate

HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. The company reported quarterly sales of $9.416 million which beat the analyst consensus estimate of $8.950 million by 5.21 percent. This is a 1.56 percent increase over sales of $9.271 million the same period last year.

HireQuest Q3 2024 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $9.416M Beat $8.950M Estimate

Donald Trump will return to the White House and will bring major changes to the country's tax, AI and energy policies. RBC Capital Markets analyst Deane Dray highlighted some of the companies that may benefit <a href="https://www.benzinga.com/government/24/11/41828468/trump-says-hed-replace-income-taxes-with-tariffs-the-potential-economic-fallout">from Trump's policies. </a>
Fossil Fuel/ Energy Independence: Trump's plans for energy independence would reverse many of the Biden administration's policies in order to reinvigorate the fossil fuel industry. He aims to expand the construction of pipelines, grids, ports and refineries and emphasizes utilizing domestic oil, gas and coal resources. Dray pointed to Flowserve Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) and Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) as potential beneficiaries of Trump's energy policies. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Rollback of IRA/ Reduced Clean Energy Investments: Trump has said he plans<a href="https://www.benzinga.com/news/24/07/39854007/trump-says-he-will-end-the-electric-vehicle-mandate-on-day-one-days-after-tesla-ceo-elon-musks-endor"> to eliminate</a> many vehicle emissions standards under the Environmental Protection Agency as well as many EV incentives included in the Biden administration&#8217;s Inflation Reduction Act (IRA). 
The RBC analyst again pointed to oil and gas companies as the key companies that could benefit from these potential policy adjustments, but cautioned it is too early to tell what the impacts might be for nuclear power companies. 
More Flexible/Reduced AI Regulation: RBC expects a Trump administration to be in favor of Big Tech and AI developers as he has called for a review of "unnecessary and burdensome regulations" on AI. The firm also pointed out that multi-industry data center-exposed stocks outperformed the sector by 500 basis points the day after Trump won the election. 
Dray said multi-industry companies involved in data centers that could benefit from Trump's less restrictive AI policies include nVent Electric Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) and Eaton Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>). 
Lower Corporate Tax Rate: Trump <a href="https://www.benzinga.com/government/24/10/41623850/trump-vs-harris-how-the-candidates-corporate-tax-proposals-stack-up">shared his plans</a> to lower the corporate tax rate to 15% for companies that make their products in the U.S. The RBC analyst sees lower corporate tax rates could lead to more reshoring from semiconductor and pharmaceutical companies and potentially more investment in the US. 
Dray pointed to Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) specifically, but most publicly traded companies could benefit from lower tax rates. 
The Takeaway: "The bottom line is that early stock moves are playing out according to script, with the early stock outperformers being the electricals and oil and gas exposed names," Dray wrote. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Shutterstock

Government

Movers

How To Play The 'Trump Trade' For AI, Energy, Taxes: Analyst Says 5 Stocks Could Shine

Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(2.03) by 10.34 percent. The company reported quarterly sales of $1.650 million which beat the analyst consensus estimate of $1.635 million by 0.92 percent. This is a 9.19 percent decrease over sales of $1.817 million the same period last year.

AVGR

Avinger Q3 2024 GAAP EPS $(1.82) Beats $(2.03) Estimate, Sales $1.650M Beat $1.635M Estimate

Globalstar (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#AMEX">GSAT</a>) raises FY2024 sales outlook from $235.00 million-$250.00 million to $245.00 million-$250.00 million.

Guidance

GSAT

Globalstar Raises FY2024 Sales Guidance from $235.00M-$250.00M to $245.00M-$250.00M

VistaGen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 36.36 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $183.000 thousand which missed the analyst consensus estimate of $223.333 thousand by 18.06 percent. This is a 34.10 percent decrease over sales of $277.700 thousand the same period last year.

VTGN

VistaGen Therapeutics Q2 2025 GAAP EPS $(0.42) Misses $(0.39) Estimate, Sales $183.000K Miss $223.333K Estimate

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) reported quarterly losses of $(1.72) per share. This is a 37.6 percent decrease over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $78.795 million which beat the analyst consensus estimate of $73.225 million by 7.61 percent. This is a 25.62 percent increase over sales of $62.723 million the same period last year.

NUTX

Nutex Health Q3 2024 GAAP EPS $(1.72) Down From $(1.25) YoY, Sales $78.795M Beat $73.225M Estimate

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.78 by 17.95 percent. The company reported quarterly sales of $23.366 billion which beat the analyst consensus estimate of $22.574 billion by 3.51 percent. This is a 8.56 percent decrease over sales of $25.552 billion the same period last year.

PBR/A

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares Q3 2024 GAAP EPS $0.92 Beats $0.78 Estimate, Sales $23.366B Beat $22.574B Estimate

MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 200 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.079 million which missed the analyst consensus estimate of $74.500 million by 5.93 percent. This is a 36.73 percent increase over sales of $51.253 million the same period last year.

MNKD

MannKind Q3 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $70.079M Miss $74.500M Estimate

Goldman Sachs BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSBD#NYSE">GSBD</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.55 by 3.64 percent. The company reported quarterly sales of $110.413 million which missed the analyst consensus estimate of $115.264 million by 4.21 percent. This is a 8.03 percent decrease over sales of $120.056 million the same period last year.

GSBD

Goldman Sachs BDC Q3 2024 Adj. EPS $0.57 Beats $0.55 Estimate, Sales $110.413M Miss $115.264M Estimate

BanColombia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIB#NYSE">CIB</a>) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.43 by 4.2 percent. The company reported quarterly sales of $1.257 billion which missed the analyst consensus estimate of $1.573 billion by 20.10 percent. This is a 4.92 percent increase over sales of $1.198 billion the same period last year.

BanColombia Q3 2024 GAAP EPS $1.49 Beats $1.43 Estimate, Sales $1.257B Miss $1.573B Estimate

The 2028 presidential election will be held on Nov. 7, 2028, and is over 1,400 days away but that hasn't stopped sportsbooks and prediction markets from forecasting who will win the next election after Donald Trump claimed victory in the<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> 2024 presidential election.</a>
2028 Election Betting Odds: While betting on U.S. elections is illegal for American sportsbooks, there are betting odds at sportsbooks around the world. Prediction markets and online stock brokerages have also<a href="https://www.benzinga.com/fintech/24/11/41783293/robinhood-reports-record-overnight-trading-volume-400-million-2024-election-contracts-traded"> launched regulated election contract options</a> in recent months.
Here is an early look at the 2028 election betting odds.
From Bookies.com, here are the current betting <a href="https://bookies.com/news/2028-us-presidential-election-odds-who-will-succeed-donald-trump">odds</a>:
<ul>
<li>J.D. Vance (Republican): +450</li>
<li>Gavin Newsom (Democrat): +575</li>
<li>Ron DeSantis (Republican): +700</li>
<li>Michelle Obama (Democrat): +950</li>
<li>Josh Shapiro (Democrat): +1,000</li>
<li>Kamala Harris (Democrat): +1,200</li>
<li>Andy Beshear (Democrat): +1,200</li>
<li>Nikki Haley (Republican): +1,200</li>
<li>Vivek Ramaswamy (Republican): +1,300</li>
<li>Wes Moore (Democrat): +1,700</li>
<li>Tom Cotton (Democrat): +1,700</li>
<li>Glenn Youngkin (Republican): +2,500</li>
<li>Aaron Rodgers (Independent): +3,000</li>
<li>Dwayne Johnson (Democrat): +3,500</li>
<li>Mark Cuban (Democrat): +3,500</li>
<li>Field (All others including Gretchen Whitmer, Marco Rubio, Ted Cruz): +2,000</li>
</ul>
Here are the current betting odds from SportsBettingDimes:
<ul>
<li>J.D. Vance (Republican): +300</li>
<li>Michelle Obama (Democrat): +500</li>
<li>Gavin Newsom (Democrat): +550</li>
<li>Ron DeSantis (Republican): +800</li>
<li>Tulsi Gabbard (Republican): +1,000</li>
<li>Hillary Clinton (Democrat): +1,400</li>
<li>Tucker Carlson (Republican): +1,400</li>
<li>Nikki Haley (Republican): +2,500</li>
<li>Oprah Winfrey (Democrat): +2,500</li>
<li>Kamala Harris (Democrat): +2,500</li>
</ul>
Bet365 does not currently list individual betting odds for who will win but has the option to bet on which party will win with Republicans favored at -150 implying a 60% chance of winning with Democrats the underdog at +120, as reported by <a href="https://www.covers.com/politics/2028-us-election-odds-republican-party-favored-nov-6-2024">Covers</a>.
Prediction market Kalshi, which is legal to U.S. bettors, also has several betting markets open for 2028 including the winning <a href="https://kalshi.com/markets/kxpresparty/party-winning-presidency">party </a>with Republicans at 49% and Democrats at 51%.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomr/republican-primary-winner">odds </a>on Kalshi for the Republican Party nominee for the 2028 election:
<ul>
<li>J.D. Vance: 57%</li>
<li>Donald Trump Jr.: 7%</li>
<li>Ron DeSantis: 6%</li>
<li>Donald Trump: 4%</li>
<li>Glenn Youngkin: 4%</li>
<li>Vivek Ramaswamy: 4%</li>
</ul>
The 22nd Amendment currently would keep Trump from serving more than two terms in the White House, but he's included in Kalshi's odds here.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomd/democratic-primary-winner#kxpresnomd-28">odds </a>on Kalshi for the Democrat Party nominee for the 2028 election:
<ul>
<li>Gavin Newsom: 16%</li>
<li>Josh Shapiro: 16%</li>
<li>Gretchen Whitmer: 14%</li>
<li>Pete Buttigieg: 11%</li>
<li>Wes Moore; 9%</li>
<li>J.B. Pritzker: 9%</li>
<li>Alexandria Ocasio-Cortez: 7%</li>
<li>Michelle Obama: 6%</li>
<li>Kamala Harris: 2%</li>
</ul>
Polymarket, which <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41694948/trump-polymarket-whale-has-30m-bet-on-former-president-winning-2024-election-my-intent-is-">had many prediction markets</a> on the 2024 election does not currently offer 2028 markets. The decentralized platform allows users to deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). The platform will be closely watched in the coming months to see who takes the early lead in 2028 election betting.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Polymarket saw over $3 billion bet on the 2024 election winner market with various other markets attracting high betting volume.
Kalshi had over $100 million wagered on<a href="https://www.benzinga.com/general/politics/24/11/41701133/more-than-100m-wagered-on-presidential-race-on-kalshi"> the 2024 election outcome.</a>
Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) had over 400 million contracts traded during the 2024 election.
While betting on the outcomes of U.S. elections is not legal at sportsbooks for America, people around the world were placing wagers along with prediction markets and brokerages trading contracts to take advantage of strong user demand.
By the time the 2028 election rolls around there could be even more betting options and election betting<a href="https://www.benzinga.com/general/sports-betting/23/05/32244769/exclusive-draftkings-benefits-from-non-nfl-sports-growth-eyes-horse-racing-and-election-be"> could be legal at sportsbooks. </a>While things could look different in the coming years, the betting odds above will likely look different as candidates decide to run or withdraw their names from consideration.
It's likely not a surprise that Vance is the early betting favorite as the future vice president won the 2024 election ticket with Trump and would be the frontrunner for the Republican Party. The big question is if Harris will run for president again and if not her, who will be the frontrunner for the Democratic Party.
Harris <a href="https://www.benzinga.com/general/sports-betting/24/10/41347270/trump-vs-harris-2024-election-polls-sportsbooks-betting-odds-show-different-winners-for-20">was the favorite </a>at +350 for the 2024 election after Joe Biden won the 2020 election as the current president originally said he would not run a second term. Biden and Trump trailed Harris in January 2021 betting odds to win the 2024 race at +400 and +650, respectively.
With Biden running again, the odds favored Biden, Trump and DeSantis, who ran in the Republican primary, for many months. With Biden dropping out, sportsbooks favored Harris before the odds shifted to Trump in the months leading up to the 2024 election.
While an Independent candidate has never won the election, the listing of Rodgers, who is the quarterback of the NFL's New York Jets, has captured some attention.
"I can't believe we live in a world where my QB has better odds to win the 2028 presidential election than my team does to win the Super Bowl," X user @blakenyjets <a href="https://x.com/blakenyjets/status/1854291783754363114">said</a>.
The New York Jets, who started the season as one of the favorites to win Super Bowl LIX, are currently 3-6 and the odds at DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) of a Super Bowl victory are +2,500 today.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41819799/polymarket-ceo-on-election-night-it-looked-like-a-done-deal-on-platform-but-just-watching-">Polymarket CEO On Election Night: &#8216;It Looked Like A Done Deal&#8217; On Platform, But Just Watching TV &#8216;You Would Think It&#8217;s Neck And Neck&#8217;</a></li>
</ul>
Photo: Meeboonstudio via Shutterstock

Sports Betting

$ETH

$MATIC

$USDC

DKNG

HOOD

USDC

2028 Election Betting Odds: Where Do J.D. Vance, Michelle Obama, Mark Cuban, Ron DeSantis, Kamala Harris Rank?

SANUWAVE Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#OTC">SNWV</a>) reported quarterly losses of $(6.49) per share. This is a 42.31 percent increase over losses of $(11.25) per share from the same period last year. The company reported $9.36 million in sales this quarter. This is a 88.98 percent increase over sales of $4.95 million the same period last year.

SNWV

SANUWAVE Health Q3 EPS $(6.49) Up From $(9.95) YoY, Sales $9.36M Up From $4.95M YoY

Freehold Royalties (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FRHLF#OTC">FRHLF</a>) reported quarterly earnings of $0.12 per share. This is a 42.86 percent decrease over earnings of $0.21 per share from the same period last year. The company reported $54.17 million in sales this quarter. This is a 13.73 percent decrease over sales of $62.79 million the same period last year.

FRHLF

Freehold Royalties Q3 EPS $0.12 Down From $0.21 YoY, Sales $54.17M Down From $62.79M YoY

The 91 rating InvestorsObserver gives to Greenwich Lifesciences Inc (GLSI)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 100 percent of stocks in the Healthcare sector, GLSIâ€&#x2122;s 91 overall rating means the stock scores better than 91 of all stocks. GLSI has an Overall Score of 91. Fi

Will Greenwich Lifesciences Inc (GLSI) Outperform the Rest of the Stocks in the Healthcare Sector?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenwich LifeSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/glsi-stock-quote/">GLSI</a>) just reported results for the fourth quarter of 2023.<ul><li>Greenwich LifeSciences reported earnings per share of -21 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/glsi-stock-earnings-greenwich-lifesciences-for-q4-of-2023/">GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenwich LifeSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/glsi-stock-quote/">GLSI</a>) just reported results for the first quarter of 2024.<ul><li>Greenwich LifeSciences reported earnings per share of -19 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/glsi-stock-earnings-greenwich-lifesciences-for-q1-of-2024/">GLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Poseida Therapeutics (PSTX – Research Report), Green...

Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)

Greenwich LifeSciences raises $2.5M, issues shares to CEO

Greenwich LifeSciences to join Russell 2000 index

Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenwich LifeSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/glsi-stock-quote/">GLSI</a>) just reported results for the second quarter of 2024.<ul><li>Greenwich LifeSciences reported earnings per share of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/glsi-stock-earnings-greenwich-lifesciences-for-q2-of-2024/">GLSI Stock Earnings: Greenwich LifeSciences Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLSI Stock Earnings: Greenwich LifeSciences Reported Results for Q2 2024

Greenwich LifeSciences files for $275M mixed securities shelf

GLSI

PSTX

RHHBF

RHHBY

RHHVF

SLRN

Press Releases

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Benitec Biopharma

Candel Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cardiff Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharma

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Gossamer Bio

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Nanobiotix

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Comments

Greenwich LifeSciences

Notizie

Ultime notizie per Greenwich LifeSciences (NASDAQ:GLSI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO